Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, February 2004, p. 689-690, Vol. 48, No. 2
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.2.689-690.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
First Canadian Salmonella enterica Serovar Typhi Isolate Harboring an Integron

LETTER
Two recent reports in this journal have described multidrug-resistant
Salmonella enterica serovar Typhi strains which harbor integrons
(
7,
9). The emergence of multidrug-resistant
S. enterica serovar
Typhi poses a serious public health concern, resulting in treatment
failures and limiting therapeutic options (
11). Multidrug-resistant
strains have been isolated in Canada from individuals returning
from Asia, primarily from India and Pakistan (
2). Recently,
an
S. enterica serovar Typhi strain was isolated from a 30-year-old
male in Ontario, Canada, suffering from bacteremia. There was
no recent history of travel; however, the patient's family had
emigrated from Sri Lanka approximately 5 years before and had
a history of typhoid fever. A strain with an indistinguishable
DNA fingerprint generated using pulsed-field gel electrophoresis
was also obtained from a stool specimen from an asymptomatic
sibling of the patient (
13). The clinical isolate, labeled N02-542,
was identified using standard biochemical and serological procedures
for enteric bacteriology (
4). Antimicrobial susceptibility testing
was performed initially using agar dilution and was repeated
using broth microdilution for additional antimicrobials (
4).
The strain was found to be resistant to ampicillin, chloramphenicol,
trimethoprim-sulfamethoxazole, streptomycin, tetracycline, and
nalidixic acid (
5) (Table
1). A second isolate from the same
blood culture specimen was also identified as
S. enterica serovar
Typhi. It was fully susceptible as determined by agar dilution,
and the fingerprint was indistinguishable from that of the resistant
isolate, suggesting that the strain had lost the multidrug-resistant
plasmid (see below). Plasmid DNA was isolated from
S. enterica serovar Typhi N02-542 with a commercial plasmid isolation kit
(Qiagen) and used to transform electrocompetent
Escherichia coli DH10B (Invitrogen). The transformant,
E. coli FJ542, was
resistant to all the same antimicrobials as the parent strain
with the exception of nalidixic acid (Table
1). Plasmid profiling
showed that
E. coli FJ542 contained the same plasmid as
S. enterica serovar Typhi N02-0542, and PCR analysis identified the presence
of the tetracycline resistance gene
tet(A)B, the chloramphenicol
resistance gene
catA1, and
blaTEM-1. PCR using primers 5'-CS
and 3'-CS to detect cassettes of class 1 integrons (
3) produced
an amplicon of approximately 750 bp in size. Sequence analysis
of the amplicon revealed a 617-bp gene cassette (
10) which had
100% identity to the cassette containing the dihydrofolate reductase
gene
dfrA7 from
Shigella flexneri (GenBank accession number
AF139109) (unpublished data). The
dfrA7 gene cassette is also
found in integrons in
E. coli plasmid pDGO100 (
1) and
E. coli plasmid R751 (
6). The
S. enterica serovar Typhi plasmid pHCM1
(218 kb) also carries
blaTEM-1,
tet(A)B, and
catA1; however,
it carries a
dfrA5 gene and an incomplete class 1 integron (
8).
The related
S. enterica serovar Typhi plasmid R27 (180 kb) contains
only the
tet(A)B gene and no class 1 integron (
12). PCR analysis
of the fully susceptible strain of
S. enterica serovar Typhi
isolated from the patient yielded no amplicons for any of the
resistance genes.
The plasmid DNA from strain FJ542(pFJ-1) was restricted with
HpaI,
EcoRI, and
BglII, and the sizes of the fragments were
used to estimate the size of pFJ-1 to be 180 kb. Southern hybridization
analysis with
tetA(B),
blaTEM,
catA1, and
dfrA7 probes confirmed
the presence of these genes on pFJ-1 (data not shown). Most
plasmids associated with
S. enterica serovar Typhi have been
shown to belong to the H1 incompatibility group, and we have
used PCR to confirm that plasmid pFJ-1 also belongs to this
group (data not shown) (
9).
In addition to the resistance gene content, the plasmid size and the compatibility group of pFJ-1 are identical to those recently described for isolates from India and Vietnam (9). This observation provides evidence to suggest that the integron-harboring plasmid has disseminated to North America. Recently, a 50-kb plasmid harboring a class 1 integron containing six drug resistance genes has been described in an S. enterica serovar Typhi isolate from Korea (7). These two findings stress the need for molecular laboratories to include an integron detection PCR for S. enterica serovar Typhi strains displaying resistance to sulfonamides, as class 1 integrons typically carry this resistance determinant (3).

ACKNOWLEDGMENTS
We thank Romeo Hizon for his contribution related to antimicrobial
susceptibility testing and Shaun Tyler and the staff of the
DNA Core Facility at the National Microbiology Laboratory for
generating the sequence information and synthesizing oligonucleotides.

REFERENCES
1 - Burnside, J. M., and D. J. Groot Obbink. 1996. Plasmid pDGO100 contains a second integron with the trimethoprim resistance gene dfrA7 as the inserted cassette. Plasmid 35:67-70.[CrossRef][Medline]
2 - Harnett, N., S. McLeod, Y. AuYong, J. Wan, S. Alexander, R. Khakhria, and C. Krishnan. 1998. Molecular characterization of multiresistant strains of Salmonella Typhi from South Asia isolated in Ontario, Canada. Can. J. Microbiol. 44:356-363.[CrossRef][Medline]
3 - Levesque, C., L. Piche, C. Larose, and P. H. Roy. 1995. PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob. Agents Chemother. 39:185-191.[Abstract]
4 - Murray, P., E. Baron, M. Pfaller, F. Tenover, and R. Yolkin. 1999. Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
5 - National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard. NCCLS M100-S12, vol. 22 no. 1; M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
6 - Ojo, K. K., D. E. Waturangi, H. A. Odelola, A. Suwanto, and S. Schwarz. 2002. Identification of a cassette-borne dfrA7-like gene that shows a 97 bp extension at the 3'-end of the reading frame. J. Antimicrob. Chemother. 49:573-574.[Free Full Text]
7 - Pai, H., J. Byeon, S. Yu, B. K. Lee, and S. Kim. 2003. Salmonella enterica serovar Typhi strains isolated in Korea containing a multidrug resistance class 1 integron. Antimicrob. Agents Chemother. 47:2006-2008.[Abstract/Free Full Text]
8 - Parkhill, J., et al. 2001. Complete genome sequence of a multidrug resistant Salmonella enterica serovar Typhi CT18. Nature 413:848-852.[CrossRef][Medline]
9 - Ploy, M. C., D. Chainier, N. H. Tran Thi, I. Poilane, P. Cruaud, F. Denis, A. Collignon, and T. Lambert. 2003. Integron-associated antibiotic resistance in Salmonella enterica serovar Typhi from Asia. Antimicrob. Agents Chemother. 47:1427-1429.[Abstract/Free Full Text]
10 - Recchia, G. D., and R. M. Hall. 1995. Gene cassettes: a new class of mobile element. Microbiology 141:3015-3027.[Free Full Text]
11 - Rowe, B., L. R. Ward, and E. J. Threlfall. 1997. Multidrug-resistant Salmonella Typhi: a worldwide epidemic. Clin. Infect. Dis. 24:S106-S109.
12 - Sherburne, C. K., T. D. Lawley, M. W. Gilmour, F. R. Blattner, V. Burland, E. Grotbeck, D. J. Rose, and D. E. Taylor. 2000. The complete DNA sequence and analysis of R27, a large IncHI plasmid from Salmonella typhi that is temperature sensitive for transfer. Nucleic Acids Res. 28:2177-2186.[Abstract/Free Full Text]
13 - Swaminathan, B., T. Barrett, S. B. Hunter, and R. Tauxe. 2001. PulseNet: the molecular subtyping network for foodborne bacterial disease surveillance, United States. Emerg. Infect. Dis. 7:382-389.[Medline]
| | | | | |
Michael R. Mulvey* David Boyd Lai-King Ng
National Microbiology Laboratory Health Canada 1015 Arlington St. Winnipeg, Manitoba R3E 3R2, Canada
Shirley Brown Marina Lombos Bruce Ciebin Aimin Li Frances Jamieson
Laboratories Branch Ontario Ministry of Health and Long-Term Care Toronto, Ontario, Canada
Philip Stuart
Canadian Medical Laboratories Mississauga, Ontario, Canada
|
| | | | | |
* Phone: (204) 789-2133, Fax: (204) 789-2018, E-mail: michael_mulvey{at}hc-sc.gc.ca |
Antimicrobial Agents and Chemotherapy, February 2004, p. 689-690, Vol. 48, No. 2
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.2.689-690.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.